Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

This study is testing whether adding a PD-1 immunotherapy drug to a combination of fruquintinib (a drug that starves tumors of blood supply) and nab-paclitaxel (a type of chemotherapy) works better than without immunotherapy as a second-line treatment for advanced stomach or gastroesophageal junction cancer. **You may be eligible if...** - You are 18 or older - You have advanced gastric (stomach) or gastroesophageal junction cancer confirmed by biopsy - You have already received at least one prior treatment, including immunotherapy (PD-1 drug) - Your general health is good (ECOG 0–1, stable within the last 7 days) - Your BMI is 18 or above - Your expected survival is at least 3 months - Your blood counts, liver, kidney, and heart function are within acceptable levels **You may NOT be eligible if...** - You have not had prior immunotherapy - You have significant organ dysfunction (heart, liver, kidneys) - Your blood counts do not meet minimum thresholds Talk to your doctor to see if this trial is right for you.